의약품 화학 시장 예측(-2032년) : 화학제품 유형별, 치료 분야별, 최종 사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Pharmaceutical Chemicals Market is accounted for $135.32 billion in 2025 and is expected to reach $227.45 billion by 2032 growing at a CAGR of 7.7% during the forecast period. Pharmaceutical chemicals form the essential foundation of today's medical treatments. They consist of active pharmaceutical ingredients (APIs), intermediates, and excipients, each serving distinct functions in drug creation. APIs deliver the primary therapeutic action, while intermediates act as transitional compounds in the synthesis of these APIs. Excipients, although not medicinally active, enhance drug performance by improving stability, taste, absorption, and durability. By providing reliable raw materials for tablets, syrups, capsules, and injectable solutions, the pharmaceutical chemical sector ensures the quality and effectiveness of medications. Ultimately, these chemicals are indispensable to global healthcare, supporting disease management, recovery, and the improvement of human health.

According to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), there are currently over 9,000 compounds at different stages of development globally. This figure highlights the immense scale of pharmaceutical R&D, where chemical synthesis and formulation play a foundational role in advancing therapeutic innovation.

Market Dynamics:

Driver:

Rising demand for generic drugs

Growing reliance on generic medicines is strongly fueling the pharmaceutical chemicals industry. With patent expirations of leading drugs, manufacturers are compelled to develop affordable alternatives that maintain the same therapeutic effectiveness as branded options. To achieve this, there is heightened demand for APIs, intermediates, and excipients that ensure quality and reliability in drug formulations. Governments and healthcare organizations actively encourage generic adoption to lower medical expenses and enhance accessibility for patients. Consequently, the production of pharmaceutical chemicals is expanding rapidly. Producers must deliver reliable, high-standard raw materials, making the generic drug wave a pivotal factor stimulating growth in this market.

Restraint:

High production and R&D costs

High manufacturing and R&D expenses pose a considerable barrier in the pharmaceutical chemicals industry. Creating new APIs, intermediates, or excipients demands cutting-edge infrastructure, specialized knowledge, and costly raw materials. The process is further burdened by regulatory filings, clinical testing, and safety trials, all of which escalate spending. Profitability often suffers as rising generic competition reduces returns, leaving many companies hesitant to invest heavily in innovation. Small and medium enterprises face the greatest risk since they lack financial stability for long-term research. Consequently, the introduction of novel chemical entities remains limited, slowing market expansion and reinforcing reliance on larger corporations with robust resources.

Opportunity:

Expansion in emerging markets

Developing economies present vast opportunities for growth in the pharmaceutical chemicals market. Nations across Asia-Pacific, Africa, and Latin America are experiencing rising incomes, expanding healthcare facilities, and larger populations, fueling higher demand for medicines. Affordable generics dominate these regions, creating strong requirements for APIs, intermediates, and excipients. Many governments are prioritizing local manufacturing to minimize imports, giving suppliers of pharmaceutical chemicals a chance to establish themselves regionally. Partnerships with domestic pharmaceutical firms further support global companies in entering these fast-growing areas. As healthcare spending and accessibility rise, emerging markets offer significant potential for long-term expansion in the pharmaceutical chemicals industry.

Threat:

Intense market competition

Fierce rivalry significantly threatens the pharmaceutical chemicals sector. Numerous regional and international firms compete by supplying APIs, intermediates, and excipients, forcing companies to cut prices while ensuring high quality. The rise of generic drug manufacturers makes the competition even tougher, as healthcare systems favor cheaper alternatives. Such conditions erode profit margins, leaving fewer funds for research and innovation. Smaller companies face the greatest risk since they lack the scale and resources of global corporations. As the battle for market share grows, maintaining profitability and distinctiveness becomes more difficult, creating long-term challenges for pharmaceutical chemical producers trying to remain competitive.

Covid-19 Impact:

The COVID-19 crisis significantly influenced the pharmaceutical chemicals industry. Supply chain interruptions delayed shipments of APIs, intermediates, and other raw materials, disrupting production for numerous pharmaceutical manufacturers. Simultaneously, the sudden surge in demand for vaccines, antiviral medications, and supportive treatments generated substantial opportunities for chemical suppliers. Firms needed to rapidly adjust production capacities, implement strict safety measures, and meet evolving regulatory requirements. Although the pandemic introduced operational and logistical obstacles, it also spurred innovation, increased investments in pharmaceutical research and development, and emphasized the essential role of pharmaceutical chemicals in healthcare systems. This period demonstrated both the vulnerabilities and strategic importance of the industry during global health emergencies.

The cardiovascular segment is expected to be the largest during the forecast period

The cardiovascular segment is expected to account for the largest market share during the forecast period. The global rise in cardiovascular disorders-such as hypertension, myocardial infarction, and stroke-drives sustained demand for related medications. Advances in drug development, including combination therapies and formulations with enhanced tolerability, further boost this demand. Moreover, as populations age worldwide, the necessity for cardiovascular treatments grows stronger. These dynamics continuously funnel investment into the synthesis of cardiovascular-specific active compounds and intermediates. As a result, the cardiovascular therapeutic area remains the foremost contributor by revenue in the pharmaceutical chemicals sector.

The contract manufacturing organizations (CMOs) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the contract manufacturing organizations (CMOs) segment is predicted to witness the highest growth rate. This rapid growth stems from the increasing tendency of pharmaceutical companies to outsource manufacturing operations to CMOs to lower costs, enhance production efficiency, and focus on research, development, and marketing. Additionally, CMOs provide expert services including active pharmaceutical ingredient (API) synthesis, formulation development, quality assurance, and packaging, which are highly sought after due to the growing demand for affordable, scalable, and reliable drug manufacturing solutions.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share. This leadership is driven by the concentration of prominent pharmaceutical firms, cutting-edge research and development facilities, and a well-established healthcare system. The United States stands out with its numerous leading pharmaceutical companies operating large-scale production plants and R&D hubs. Furthermore, favorable patent laws and intellectual property protections encourage innovation within the region. North America's emphasis on creating novel therapeutics and biomarkers, along with adherence to rigorous quality standards enforced by agencies such as the U.S. FDA, solidifies its dominant role in the pharmaceutical chemicals sector.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Key drivers include increased healthcare expenditure, the expansion of pharmaceutical manufacturing capacities, and a heightened need for active pharmaceutical ingredients (APIs) in developing economies. Nations such as China and India are leading this growth, bolstered by substantial investments in research and development and the presence of a robust pharmaceutical industry. Furthermore, the region's large and aging population, coupled with a rising incidence of chronic diseases, is fueling the demand for pharmaceutical chemicals. Consequently, the APAC region is poised for significant market growth in the coming years.

Key players in the market

Some of the key players in Pharmaceutical Chemicals Market include Sun Pharma, Dr. Reddy's Labs, Aurobindo Pharma, Cipla, Zydus Life, Lupin, Biocon, Glenmark Pharma, Alkem Lab, Torrent Pharma, Divis Labs, Piramal Pharma, Ipca Labs, Aarti Industries and Kajay Remedies.

Key Developments:

In July 2025, Sun Pharmaceutical Industries Ltd has announced that it has entered into a settlement and license agreement with Incyte Corporation regarding litigation related to LEQSELVI. Under the terms of agreement, the parties will seek dismissal of the pending LEQSELVI litigation in the United States District Court for the District of New Jersey and Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation.

In February 2025, Dr Reddy's Laboratories has signed a licence agreement with Shanghai Henlius Biotech to develop and commercialise HLX15, a daratumumab biosimilar candidate to Johnson & Johnson's (J&J) Darzalex & Darzalex Faspro. Darzalex & Darzalex Faspro are indicated to treat multiple myeloma. The partnership leverages Dr. Reddy's worldwide commercial network along with Henlius' expertise in biosimilar development.

In November 2024, Aurobindo Pharma's US faction has entered into collaboration and licensing agreement with a global pharmaceutical company. The agreement will focus on the development of respiratory therapeutics, with associated costs being shared equally between the partners. The development period is predicted to span around three to five years, with Aurobindo's total spend in this portion of the deal capped at USD $90m.

Chemical Types Covered:

• Active Pharmaceutical Ingredients (APIs)
• Excipients
• Intermediates
• Solvents
• Reagents

Therapeutic Areas Covered:

• Oncology
• Cardiovascular
• Central Nervous System (CNS)
• Infectious Diseases
• Endocrinology
• Respiratory
• Dermatology
• Gastroenterology
• Other Therapeutic Areas

End Users Covered:

• Pharmaceutical Manufacturers
• Contract Manufacturing Organizations (CMOs)
• Pharmaceutical R&D Institutions
• Chemical Suppliers & Distributors

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Pharmaceutical Chemicals Market, By Chemical Type

• 5.1 Introduction
• 5.2 Active Pharmaceutical Ingredients (APIs)
  • 5.2.1 Synthetic APIs
  • 5.2.2 Biotech APIs
• 5.3 Excipients
• 5.4 Intermediates
• 5.5 Solvents
• 5.6 Reagents

6 Global Pharmaceutical Chemicals Market, By Therapeutic Area

• 6.1 Introduction
• 6.2 Oncology
• 6.3 Cardiovascular
• 6.4 Central Nervous System (CNS)
• 6.5 Infectious Diseases
• 6.6 Endocrinology
• 6.7 Respiratory
• 6.8 Dermatology
• 6.9 Gastroenterology
• 6.10 Other Therapeutic Areas

7 Global Pharmaceutical Chemicals Market, By End User

• 7.1 Introduction
• 7.2 Pharmaceutical Manufacturers
• 7.3 Contract Manufacturing Organizations (CMOs)
• 7.4 Pharmaceutical R&D Institutions
• 7.5 Chemical Suppliers & Distributors

8 Global Pharmaceutical Chemicals Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Sun Pharma
• 10.2 Dr. Reddy's Labs
• 10.3 Aurobindo Pharma
• 10.4 Cipla
• 10.5 Zydus Life
• 10.6 Lupin
• 10.7 Biocon
• 10.8 Glenmark Pharma
• 10.9 Alkem Lab
• 10.10 Torrent Pharma
• 10.11 Divis Labs
• 10.12 Piramal Pharma
• 10.13 Ipca Labs
• 10.14 Aarti Industries
• 10.15 Kajay Remedies